BridgeBio to Participate in September Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio (Nasdaq: BBIO) announced that its management team will participate in several healthcare investor conferences in September 2026, including events hosted by Wells Fargo, Cantor, Morgan Stanley, and Bernstein in Boston and New York on dates between September 9 and September 23.
Live webcasts of the fireside chats will be available via the Investors “Events and Presentations” page on BridgeBio’s website, with replays accessible for 90 days. BridgeBio describes itself as a commercial-stage biopharmaceutical company developing medicines for genetic conditions using a decentralized hub-and-spoke model.
Details
News Market Reaction – BBIO
On Sep 1, the day this news came out, BBIO closed 0.03% below the previous close.
Data tracked by StockTitan Argus for the Sep 1 session.
Key Figures
- Wells Fargo conference slot
- 21st annual; September 9, 2026 at 1:30 pm EDT
- Healthcare investor conference
- Cantor conference slot
- 2026; September 10, 2026 at 9:10 am EDT
- Global healthcare conference
- Morgan Stanley conference slot
- 24th annual; September 15, 2026 at 10:00 am EDT
- Global healthcare conference
- Bernstein conference slot
- 2026; September 23, 2026 at 9:40 am EDT
- Healthcare leaders and disruptors conference
- Webcast replay availability
- 90 days
- Following each event
Historical Context
-
Agreement aimed to expand Medicaid access and lower medicine costs for American patients.
-
First participant received treatment in long-term acoramidis ATTR-CM study.
-
Company announced new open-label extension analyses and additional conference presentations.
-
Existing shareholder priced a 5,000,000-share secondary offering without company proceeds.
-
Existing shareholder launched a 5,000,000-share offering under an automatic shelf registration.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:
- 21st Annual Wells Fargo Healthcare Conference, Boston, MA: Wednesday, September 9 at 1:30 pm EDT
- 2026 Cantor Global Healthcare Conference, New York, NY: Thursday, September 10 at 9:10 am EDT
- Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Tuesday, September 15 at 10:00 am EDT
- Bernstein Insights Healthcare Leaders and Disruptors 2026, New York, NY: Wednesday, September 23 at 9:40am EDT
To access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.